Suggested remit: To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating interstitial lung disease caused by systemic sclerosis.
Following on from information provided to NICE by the company in July 2020 the appraisal of Lung disease (interstitial, systemic sclerosis) - nintedanib (Boehringer Ingleheim) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1420
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Lung disease (interstitial, systemic sclerosis) - nintedanib (Boehringer Ingleheim) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 September 2020 | Note added to the project documents |
| 01 September 2020 | Suspended. Topic is suspended |
| 01 September 2020 | Note added to the project documents |
| 20 June 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. Please note that following on from advice received from the company, information regarding the timelines for this appraisal will be available in due course. |
| 11 January 2019 (14:30) | Scoping workshop (London) |
| 15 November 2018 - 13 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual